This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Seattle Genetics To Present Clinical Data From Broad ADCETRIS® (Brentuximab Vedotin) Development Program And Novel Antibody-Drug Conjugate (ADC) SGN-CD19A At ASH 2013

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013, highlighting the following:

  • Clinical data for ADCETRIS (brentuximab vedotin) in CD30-positive lymphomas, including Hodgkin lymphoma (HL), mature T-cell lymphoma (MTCL), cutaneous T-cell lymphoma (CTCL) and diffuse B-cell lymphoma (DLBCL);
  • Interim phase 1 clinical data for SGN-CD19A, a novel antibody-drug conjugate (ADC), in acute lymphoblastic leukemia (ALL); and
  • Final phase 1 data from two ADC candidates that utilize Seattle Genetics’ proprietary technology being developed by Genentech, a member of the Roche Group (SIC: RO, ROG; OTCQX: RHHBY), including an anti-CD22 ADC (pinatuzumab vedotin, RG7593) and an anti-CD79b ADC (polatuzumab vedotin, RG7596).

“The presentations at ASH demonstrate the breadth of our development program for ADCETRIS in CD30-positive malignancies, including frontline and relapsed patients and disease areas ranging from Hodgkin lymphoma to mature T-cell lymphoma and diffuse large B-cell lymphoma,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. “Beyond ADCETRIS, we continue to make progress in advancing our robust ADC pipeline, including SGN-CD19A, which is currently being evaluated in ALL and aggressive non-Hodgkin lymphoma. Finally, our collaborators continue to advance potential therapeutic options for patients and are making progress with ADCs utilizing our technology.”

ADCETRIS is an ADC directed to CD30, which is known to be expressed in HL and systemic anaplastic large cell lymphoma (sALCL), as well as in many types of CTCL, B-cell lymphomas and MTCL. Across corporate and investigator-sponsored trials, ADCETRIS is being evaluated in more than 20 ongoing clinical trials, including four phase 3 studies. ADCETRIS is currently not approved for use in CTCL, B-cell non-Hodgkin lymphoma, salvage HL or frontline treatment of MTCL and HL.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs